Pfizer wins Norvasc patent lawsuit

A federal court jury in the Eastern District of Virginia ruled unanimously that Pfizer did not infringe Synthon IP’s US patent covering a process for making amlodipine, the active ingredient in the blockbuster blood pressure drug Norvasc. Norvasc is the world’s most-prescribed branded medicine for treating hypertension, with $4.7 billion in global sales last year and is Pfizer's second-best-selling drug behind the cholesterol treatment Lipitor (atorvastatin calcium). “Today’s unanimous decisions underscore our determination to defend our products against unwarranted attacks and to support research-based medical innovations that benefit millions of patients,” said Allen Waxman, Pfizer’s general counsel. Synthon IP is a US subsidiary of Dutch company Synthon BV, which brought its suit against Pfizer in November 2005, asserting that Pfizer infringed a Synthon patent issued in 2003. This patent, Synthon claimed, covered Pfizer’s process for making amlodipine – a process Pfizer claimed to have been using for more than 15 years.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions